Type 2 Diabetes: Outpatient Insulin Management

Sarah Tucker Marrison, MD, PhD
Scott Bragg, PharmD
Emmeline Tran, PharmD

American Family Physician. 2026;113(6):542-550.

Author disclosure: No relevant financial relationships.

This clinical content conforms to AAFP criteria for CME.

More than 29 million adults in the United States are diagnosed with type 2 diabetes, and insulin therapy is estimated to be needed in up to 15% of cases. Insulin should be considered first-line treatment in patients with severe hyperglycemia (eg, A1C greater than 10%, blood glucose 300 mg/dL or higher), symptoms of hyperglycemia, or catabolism. To optimize insulin use in an outpatient setting, family physicians must consider strategies for initiation, titration, and adherence. The preferred starting regimen is basal insulin with stepwise intensification to prandial or premixed insulin. Insulin regimens can be titrated as frequently as every 2 to 3 days until blood glucose targets are reached. Long-acting insulin analogues offer improved duration of action and reduced risk of hypoglycemia compared with intermediate-acting insulin. Continuous glucose monitoring may improve diabetes control and can be considered in patients who need insulin. Weight gain, hypoglycemia, and insulin regimen complexity are key challenges in diabetes management. Family physicians should use individualized targets that consider life expectancy, age, medical comorbidities, and hypoglycemia risk. Insulin treatment remains a significant but complex aspect of managing type 2 diabetes.

SARAH TUCKER MARRISON, MD, PhD, is an assistant professor in the Department of Family Medicine at the Medical University of South Carolina, Charleston.

SCOTT BRAGG, PharmD, is a professor in the Department of Clinical Pharmacy and Outcomes Sciences and the Department of Family Medicine at the Medical University of South Carolina, Charleston.

EMMELINE TRAN, PharmD, is an associate professor in the Department of Clinical Pharmacy and Outcomes Sciences at the Medical University of South Carolina, Charleston.

Address correspondence to Sarah Tucker Marrison, MD, PhD, at marrison@musc.edu.

Author disclosure: No relevant financial relationships.

  1. 1.US Centers for Disease Control and Prevention. National diabetes statistics report. January 21, 2026. Accessed March 31, 2026. https://www.cdc.gov/diabetes/php/data-research/index.html
  2. 2.Howard-Thompson A, Khan M, Jones M, et al. Type 2 diabetes mellitus: outpatient insulin management. Am Fam Physician. 2018;97(1):29-37.
  3. 3.Vijan S. Type 2 diabetes. Ann Intern Med. 2019;171(9):ITC65-ITC80.
  4. 4.Lv C, Sun Y, Zhang ZY, et al. β-cell dynamics in type 2 diabetes and in dietary and exercise interventions. J Mol Cell Biol. 2022;14(7):mjac046.
  5. 5.Basu S, Yudkin JS, Kehlenbrink S, et al. Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysis. Lancet Diabetes Endocrinol. 2019;7(1):25-33.
  6. 6.Boonpattharatthiti K, Saensook T, Neelapaijit N, et al. The prevalence of adherence to insulin therapy in patients with diabetes: a systematic review and meta-analysis. Res Social Adm Pharm. 2024;20(3):255-295.
  7. 7.Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm—2023 update. Endocr Pract. 2023;29(5):305-340.
  8. 8.American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026. Diabetes Care. 2026;49:S183-S215.
  9. 9.American Diabetes Association Professional Practice Committee. 6. Glycemic goals and hypoglycemia: standards of care in diabetes—2026. Diabetes Care. 2026;49:S132-S149.
  10. 10.Durnwald C, Beck RW, Li Z, et al. Continuous glucose monitoring profiles in pregnancies with and without gestational diabetes mellitus. Diabetes Care. 2024;47(8):1333-1341.
  11. 11.Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update. Endocr Pract. 2022;28(10):923-1049.
  12. 12.American Diabetes Association Professional Practice Committee. 15. Management of diabetes in pregnancy: standards of care in diabetes—2026. Diabetes Care. 2026;49:S321-S338.
  13. 13.Grube D, Wei G, Boucher R, et al. Insulin use in chronic kidney disease and the risk of hypoglycemic events. BMC Nephrol. 2022;23(1):73.
  14. 14.Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5):S1-S127.
  15. 15.15 American Diabetes Association Professional Practice Committee. 13. Older adults: standards of care in diabetes—2026. Diabetes Care. 2026;49:S277-S296.
  16. 16.Semlitsch T, Engler J, Siebenhofer A, et al. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020(11):CD005613.
  17. 17.Tibaldi JM. Evolution of insulin: from human to analog. Am J Med. 2014;127(10):S25-S38.
  18. 18.Fullerton B, Siebenhofer A, Jeitler K, et al. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2018(12):CD013228.
  19. 19.Kitabchi AE, Gosmanov AR. Safety of rapid-acting insulin analogs versus regular human insulin. Am J Med Sci. 2012;344(2):136-141.
  20. 20.Wong EY, Kroon L. Ultra-rapid-acting insulins: how fast is really needed?. Clin Diabetes. 2021;39(4):415-423.
  21. 21.Pharmacy Times. FDA approves insulin icodec-abae, first once-weekly basal insulin for adults with T2D. March 27, 2026. Accessed April 2, 2026. https://www.pharmacytimes.com/view/fda-approves-insulin-icodec-abae-first-once-weekly-basal-insulin-for-adults-with-t2d
  22. 22.Rosenstock J, Bain SC, Gowda A, et al.; ONWARDS 1 Trial Investigators. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med. 2023;389(4):297-308.
  23. 23.Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023;11(6):414-425.
  24. 24.Lingvay I, Asong M, Desouza C, et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes: the ONWARDS 3 randomized clinical trial. JAMA. 2023;330(3):228-237.
  25. 25.Mathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet. 2023;401(10392):1929-1940.
  26. 26.Bajaj HS, Aberle J, Davies M, et al. Once-weekly insulin icodec with dosing guide app versus once-daily basal insulin analogues in insulin-naive type 2 diabetes (ONWARDS 5): a randomized trial. Ann Intern Med. 2023;176(11):1476-1485.
  27. 27.de la Peña A, Riddle M, Morrow LA, et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care. 2011;34(12):2496-2501.
  28. 28.Wysham C, Hood RC, Warren ML, et al. Effect of total daily dose on efficacy, dosing, and safety of 2 dose titration regimens of human regular U500 insulin in severely insulin-resistant patients with type 2 diabetes. Endocr Pract. 2016;22(6):653-665.
  29. 29.White J, Goldman J. Biosimilar and follow-on insulin: the ins, outs, and interchangeability. J Pharm Technol. 2019;35(1):25-35.
  30. 30.US Food and Drug Administration. Biosimilars: overview for health care professionals. August 2024. Accessed October 17, 2025. https://www.fda.gov/drugs/biosimilars/overview-health-care-professionals
  31. 31.Mooradian AD, Bernbaum M, Albert SG. Narrative review: a rational approach to starting insulin therapy. Ann Intern Med. 2006;145(2):125-134.
  32. 32.Umpierrez GE, Davis GM, El Sayed NA, et al. Hyperglycemic crises in adults with diabetes: a consensus report. Diabetes Care. 2024;47(8):1257-1275.
  33. 33.Tentolouris N, Kyriazopoulou V, Makrigiannis D, et al. Intensification of insulin therapy in patients with type 2 diabetes: a retrospective, non-interventional cohort study of patients treated with insulin glargine or biphasic human insulin in daily clinical practice. Diabetol Metab Syndr. 2013;5:43.
  34. 34.Vora J, Cohen N, Evans M, et al. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape). Diabetes Obes Metab. 2015;17(12):1133-1141.
  35. 35.Boonpattharatthiti K, Wechkunanukul K, Mayang N, et al. Comparison of insulin titration strategies for glycemic control in type 2 diabetes: a systematic review and network meta-analysis. Diabetes Care. 2025;48(5):837-845.
  36. 36.Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest. 1988;81(2):442-448.
  37. 37.Harper R, Bashan E, Williams KJ, et al. Challenging the 50-50 rule for the basal-bolus insulin ratio in patients with type 2 diabetes who maintain stable glycaemic control. Diabetes Obes Metab. 2023;25(2):581-585.
  38. 38.Chun J, Strong J, Urquhart S. Insulin initiation and titration in patients with type 2 diabetes. Diabetes Spectr. 2019;32(2):104-111.
  39. 39.Ovalle F. Clinical approach to the patient with diabetes mellitus and very high insulin requirements. Diabetes Res Clin Pract. 2010;90(3):231-242.
  40. 40.Vaughan EM, Santiago-Delgado ZM. Management of type 2 diabetes mellitus with noninsulin pharmacotherapy. Am Fam Physician. 2024;109(4):333-342.
  41. 41.Chen M, Vider E, Plakogiannis R. Insulin dosage adjustments after initiation of GLP-1 receptor agonists in patients with type 2 diabetes. J Pharm Pract. 2022;35(4):511-517.
  42. 42.Lahey AM, Duprey K, Montague RC, et al. Insulin requirements after switching from GLP-1 receptor agonist to dual GIP/GLP-1 receptor agonist in patients with type 2 diabetes mellitus. Pharmacotherapy. 2025;45(4):220-226.
  43. 43.George J, Lobkovich A, Nardolillo J, et al. Real-world evaluation of insulin requirements after GLP1 agonist or SGLT2 inhibitor initiation and titration. Am J Health Syst Pharm. 2022;79(14):1151-1157.
  44. 44.Moulton MK, Johnson BR, Lavender DL, et al. A scoping review evaluating the effect of SGLT-2 inhibitors on insulin dose requirements in insulin-dependent patients with type 2 diabetes. Ann Pharmacother. 2022;56(9):1030-1040.
  45. 45.Van Dril E, Allison M, Schumacher C. Deprescribing in type 2 diabetes and cardiovascular disease: recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy. Am Heart J Plus. 2022;17:100163.
  46. 46.Hinnen DA. Therapeutic options for the management of postprandial glucose in patients with type 2 diabetes on basal insulin. Clin Diabetes. 2015;33(4):175-180.
  47. 47.Yamanouchi T. Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes. Vasc Health Risk Manag. 2010;6:189-197.
  48. 48.McKone DB, Duprey KS, Hall HM, et al. Evaluation of insulin dosage after the addition of tirzepatide compared with semaglutide or dulaglutide in patients with type 2 diabetes. Diabetes Spectr. 2025;38(3):266-273.
  49. 49.American Diabetes Association Professional Practice Committee. 7. Diabetes technology: standards of care in diabetes—2026. Diabetes Care. 2026;49:S150-S165.
  50. 50.Skriver LKL, Nielsen MW, Walther S, et al. Factors associated with adherence or nonadherence to insulin therapy among adults with type 2 diabetes mellitus: a scoping review. J Diabetes Complications. 2023;37(10):108596.
  51. 51.Prinz N, Schwandt A, Borgert B, et al. Not all type-2-diabetes patients increase body mass index after initiating insulin: results of latent class analysis from the DPV registry. Diabetes Technol Ther. 2021;23(12):799-806.
  52. 52.Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes study group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
  53. 53.American Diabetes Association Professional Practice Committee for Diabetes. 1. Improving care and promoting health in populations: standards of care in diabetes-2026. Diabetes Care. 2026;49:S13-S26.
  54. 54.Galdón Sanz-Pastor A, Justel Enríquez A, Sánchez Bao A, et al. Current barriers to initiating insulin therapy in individuals with type 2 diabetes. Front Endocrinol (Lausanne). 2024;15:1366368.
  55. 55.Flint KL, Marcondes FO. Achieving digital health equity in diabetes care. Endocr Pract. 2024;30(8):765-767.
  56. 56.Barnard-Kelly KD, Martinez-Brocca MA, Glatzer T, et al. Identifying the deficiencies of currently available CGM to improve update and benefit. Diabet Med. 2024;41(8):e15338.
  57. 57.Seidu S, Kunutsor SK, Ajjan RA, et al. Efficacy and safety of continuous glucose monitoring and intermittently scanned continuous glucose monitoring in patients with type 2 diabetes: a systematic review and meta-analysis of interventional evidence. Diabetes Care. 2024;47(1):169-179.
  58. 58.Bergenstal RM, Beck RW, Close KL, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41(11):2275-2280.
  59. 59.Rosenstock J, Juneja R, Beals JM, et al. The basis for weekly insulin therapy: evolving evidence with insulin icodec and insulin efsitora alfa. Endocr Rev. 2024;45(3):379-413.
  60. 60.Spoorthi Shetty S, Halagali P, Johnson AP, et al. Oral insulin delivery: barriers, strategies, and formulation approaches: a comprehensive review. Int J Biol Macromol. 2023;242:125114.
  61. 61.Freckmann G, Buck S, Waldenmaier D, et al. Insulin pump therapy for patients with type 2 diabetes mellitus: evidence, current barriers, and new technologies. J Diabetes Sci Technol. 2021;15(4):901-915.
  62. 62.Petznick A. Insulin management of type 2 diabetes mellitus. Am Fam Physician. 2011;84(2):183-190.
  63. 63.Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician. 2004;70(3):489-500.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.